Equillium, Inc.
NASDAQEquillium heads into its May 19 earnings event with a rare dynamic for a micro-cap biotech: a unanimous analyst buy consensus colliding with a lending market that is growing meaningfully tighter. The borrow story is the lead here. Availability has dropped to just 46% — meaning less than one share remains available to borrow for every two already lent out — a level that puts pressure…
Snapshot as of 16 May 2026
Equillium heads into its May 19 earnings event with a rare dynamic for a micro-cap biotech: a unanimous analyst buy consensus colliding with a lending market that is growing meaningfully tighter. The borrow story is…
Equillium just delivered its Q1 2026 results — and the headline is a miss. The company reported EPS of $(0.06) against a consensus estimate of $(0.04) to $(0.05), a shortfall that lands on the same evening the stock…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for EQ — free to start on ORTEX.
Sign up for free →Open EQ on ORTEX